The Albert B. Sabin Vaccine Institute, Inc.

Improving lives through immunization

aka Sabin Vaccine Institute   |   Washington, DC   |  www.sabin.org

Mission

Our mission is to make vaccines more accessible, enable innovation and expand immunization across the globe.

We seek a future free from vaccine-preventable diseases.

We deliver sustainable, evidence-based solutions that extend the benefits of immunization to everyone, everywhere.

Ruling year info

1994

Chief Executive Officer

Amy Finan

Main address

2175 K Street NW Suite 400

Washington, DC 20037 USA

Show more contact info

EIN

06-1389829

NTEE code info

Research Institutes and/or Public Policy Analysis (U05)

Specifically Named Diseases Research (H80)

Public Health Program (E70)

IRS filing requirement

This organization is required to file an IRS Form 990 or 990-EZ.

Sign in or create an account to view Form(s) 990 for 2019, 2018 and 2017.
Register now

Communication

Programs and results

What we aim to solve

SOURCE: Self-reported by organization

Vaccines are one of the most successful health innovations in recent history, but the world is failing to reap the full benefits of immunization.

Childhood vaccination saves up to 3 million lives every year, but 1.5 million people still die each year from diseases that could have been prevented by vaccines.

Immunization is a best buy in global health, with a return of $16 for every $1 spent on immunization for the world's poorest children. When we account for broader economic and social benefits, the return on investment is much greater — up to 44 times the cost of vaccination.

Despite the enormous health and economic potential of vaccines, the world is failing to ensure everyone benefits from the promise of vaccines. One in seven children are missing out on basic vaccines. Now is the time to support countries to establish sustainable immunization programs to reach every child.

Successful immunization programs are the foundation of health care in every country in the world.

Our programs

SOURCE: Self-reported by organization

What are the organization's current programs, how do they measure success, and who do the programs serve?

Global Immunization

Through our role at the intersection of immunization programs, policy and research, Sabin strives to empower immunization professionals, foster innovative thinking to advance next-generation vaccines, build public trust and ensure that vaccines reach every person that needs them.

Population(s) Served

Sabin is working to advance the development of vaccine candidates targeting diseases that impact the world's most vulnerable populations and is committed to ensuring equitable access to vaccines resulting from its R&D work.

Population(s) Served

Where we work

Our results

SOURCE: Self-reported by organization

How does this organization measure their results? It's a hard question but an important one.

Total number of organization members

This metric is no longer tracked.
Totals By Year
Type of Metric

Output - describing our activities and reach

Direction of Success

Increasing

Context Notes

Boost is the only global network for immunization professionals and currently includes nearly 1000 active members from over 115 countries. Tailored to immunization professionals, Boost provides intera

Goals & Strategy

SOURCE: Self-reported by organization

Learn about the organization's key goals, strategies, capabilities, and progress.

Charting impact

Four powerful questions that require reflection about what really matters - results.

Lasting solutions cannot be imposed; they must be built. That is why we are dedicated to the development of country-driven, evidence-based responses to the world's leading health problems.

At Sabin, we believe in the power of vaccines to change the world. We seek a future free from vaccine-preventable diseases. We deliver sustainable, evidence-based solutions that extend the benefits of immunization to everyone, everywhere.

We carry on the legacy of Dr. Albert B. Sabin, best known for his creation of the oral polio vaccine in the 1950s, which was used in the global effort to eradicate polio. His vaccine saved countless millions around the world from death and disability, thanks to Dr. Sabin's tireless commitment to ensure that every child was protected from preventable disease. This dedication to reach every child with life-saving vaccines continues to inspire our work today.

Global Immunization

Through our role at the intersection of immunization programs, policy and research, Sabin strives to empower immunization professionals, foster innovative thinking to advance next-generation vaccines, build public trust and ensure that vaccines reach every person that needs them.

Vaccine Research & Development

Sabin is working to advance the development of vaccine candidates targeting diseases that impact the world's most vulnerable populations and is committed to ensuring equitable access to vaccines resulting from its R&D work.

The Sabin Vaccine Institute is a leading advocate for expanding vaccine access and uptake globally, advancing vaccine research and development, and amplifying vaccine knowledge and innovation.

Unlocking the potential of vaccines through partnership, Sabin has built a robust ecosystem of funders, innovators, implementers, practitioners, policy makers and public stakeholders to advance its vision of a future free from preventable diseases.

As a non-profit with more than two decades of experience, Sabin is committed to finding solutions that last and extending the full benefits of immunization to all people, regardless of who they are or where they live.

Typhoid

A new typhoid conjugate vaccine protecting children as young as 6 months of age offers the prospect of reducing the impact of this frequently overlooked disease — causing an estimated 128,000 deaths annually. Sabin’s landmark study to establish the burden of enteric fever on Southeast Asian communities and health care systems is providing key evidence to support introduction of this new vaccine into routine immunization schedules.

Ebola Sudan and Marburg

The Sudan strain of Ebola, along with the closely-related Marburg virus, are among the world’s deadliest diseases, causing hemorrhagic fever and death in an average of 50 percent of cases. With $20 million in initial funding from the U.S. Department of Health and Human Services, Sabin plans to advance an investigational vaccine through Phase 2 clinical trials.

Vaccine Acceptance

Delay or refusal of vaccination is one of the 10 greatest threats to our health, according to the World Health Organization. Through a series of grant-making programs, social and behavioral research, media education initiatives and
public advocacy campaigns, Sabin is a catalyst for informed decision making that boosts vaccine access and confidence.

Influenza

The next influenza pandemic could take an unprecedented toll: an estimated 33 million deaths within six months and a $6 trillion cost to the global economy. A universal influenza vaccine is key to preventing such devastation, but it remains an enormous challenge. By bringing together problem solvers from the worlds of science, technology and business, Sabin is creating a movement to address obstacles to vaccine development and make influenza history.

How we listen

SOURCE: Self-reported by organization

Seeking feedback from people served makes programs more responsive and effective. Here’s how this organization is listening.

done We shared information about our current feedback practices.
  • How is your organization collecting feedback from the people you serve?

    Electronic surveys (by email, tablet, etc.), Paper surveys, Community meetings/Town halls, Constituent (client or resident, etc.) advisory committees, Suggestion box/email,

  • How is your organization using feedback from the people you serve?

    To identify and remedy poor client service experiences, To identify bright spots and enhance positive service experiences, To make fundamental changes to our programs and/or operations, To inform the development of new programs/projects, To identify where we are less inclusive or equitable across demographic groups, To strengthen relationships with the people we serve,

  • With whom is the organization sharing feedback?

  • What challenges does the organization face when collecting feedback?

Financials

The Albert B. Sabin Vaccine Institute, Inc.
lock

Unlock financial insights by subscribing to our monthly plan.

Subscribe

Unlock nonprofit financial insights that will help you make more informed decisions. Try our monthly plan today.

  • Analyze a variety of pre-calculated financial metrics
  • Access beautifully interactive analysis and comparison tools
  • Compare nonprofit financials to similar organizations

Want to see how you can enhance your nonprofit research and unlock more insights?
Learn more about GuideStar Pro.

Operations

The people, governance practices, and partners that make the organization tick.

lock

Connect with nonprofit leaders

Subscribe

Build relationships with key people who manage and lead nonprofit organizations with GuideStar Pro. Try a low commitment monthly plan today.

  • Analyze a variety of pre-calculated financial metrics
  • Access beautifully interactive analysis and comparison tools
  • Compare nonprofit financials to similar organizations

Want to see how you can enhance your nonprofit research and unlock more insights? Learn More about GuideStar Pro.

lock

Connect with nonprofit leaders

Subscribe

Build relationships with key people who manage and lead nonprofit organizations with GuideStar Pro. Try a low commitment monthly plan today.

  • Analyze a variety of pre-calculated financial metrics
  • Access beautifully interactive analysis and comparison tools
  • Compare nonprofit financials to similar organizations

Want to see how you can enhance your nonprofit research and unlock more insights? Learn More about GuideStar Pro.

The Albert B. Sabin Vaccine Institute, Inc.

Board of directors
as of 11/2/2020
SOURCE: Self-reported by organization
Board chair

Dr. Axel Hoos

GlaxoSmithKline

Axel Hoos

Glaxo Smith Kline Pharmaceuticals

Philip Russell

Medical Researcher, Educator

Peter Thoren

Access Industries

Regina Rabinovich

Harvard University

Wendy Holman

Ridgeback Biotherapeutics

Filip Dubovsky

Sabin Vaccine Institute

Elizabeth Fox

Pan American Development Foundation

Jeffrey Libson

Cooley LLP

Saad Omer

Yale Institute of Global Health

David Salisbury

Global Health Security at Chatham House

Jacqueline Shea

Inovio Pharmaceuticals, Inc

Board leadership practices

SOURCE: Self-reported by organization

GuideStar worked with BoardSource, the national leader in nonprofit board leadership and governance, to create this section.

  • Board orientation and education
    Does the board conduct a formal orientation for new board members and require all board members to sign a written agreement regarding their roles, responsibilities, and expectations? Yes
  • CEO oversight
    Has the board conducted a formal, written assessment of the chief executive within the past year ? Yes
  • Ethics and transparency
    Have the board and senior staff reviewed the conflict-of-interest policy and completed and signed disclosure statements in the past year? Yes
  • Board composition
    Does the board ensure an inclusive board member recruitment process that results in diversity of thought and leadership? Yes
  • Board performance
    Has the board conducted a formal, written self-assessment of its performance within the past three years? Yes